Literature DB >> 15967059

Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment.

Matthew N Hill1, Jane C Sun, Maric T L Tse, Boris B Gorzalka.   

Abstract

This study examined the effects of long-term cannabinoid administration on the responsivity of 5-HT1A and 5-HT2A receptors, which have been implicated in depression. Animals received 12 d administration of the potent cannabinoid receptor agonist HU-210 (100 microg/kg), following which they were monitored on their behavioural, physiological and hormonal responses to a single challenge of a 5-HT1A and 5-HT2A receptor agonist, 8-OH-DPAT (0.3 mg/kg) and DOI (1 mg/kg) respectively. Chronic HU-210 treatment lead to a significant enhancement of DOI-induced wet-dog shakes, but a reduction of DOI-induced back muscle contractions. DOI-induced corticosterone release was unaffected by HU-210 treatment. The hyperthermic response to DOI appeared to be potentiated by long-term HU-210 treatment, as 50% of these subjects died from an apparent serotonin syndrome with core temperatures exceeding 43 degrees C. The 8-OH-DPAT-induced hypothermic response and elevation of corticosterone were both significantly attenuated by long- term HU-210 treatment. These data imply that chronic cannabinoid treatment may up-regulate 5-HT2A receptor activity while concurrently down-regulating 5-HT1A receptor activity, a finding similar to that sometimes observed in depression. This may partially explain the association between excessive cannabis consumption and the induction of affective disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967059     DOI: 10.1017/S1461145705005651

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  28 in total

1.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 2.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

3.  Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.

Authors:  Francis Rodriguez Bambico; Tommaso Cassano; Sergio Dominguez-Lopez; Noam Katz; Claire Dominique Walker; Daniele Piomelli; Gabriella Gobbi
Journal:  Neuropsychopharmacology       Date:  2010-06-23       Impact factor: 7.853

Review 4.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

Review 5.  The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Authors:  Christina A Brezing; Frances R Levin
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

6.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

7.  Emotion regulation deficits in regular marijuana users.

Authors:  Kaeli Zimmermann; Christina Walz; Raissa T Derckx; Keith M Kendrick; Bernd Weber; Bruce Dore; Kevin N Ochsner; René Hurlemann; Benjamin Becker
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

8.  Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors.

Authors:  J M Franklin; T Vasiljevik; T E Prisinzano; G A Carrasco
Journal:  Eur Neuropsychopharmacol       Date:  2012-07-28       Impact factor: 4.600

9.  Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  Synapse       Date:  2012-12-08       Impact factor: 2.562

10.  A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

Authors:  Aimee L McRae-Clark; Rickey E Carter; Therese K Killeen; Matthew J Carpenter; Amy E Wahlquist; Stacey A Simpson; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2009-08-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.